Immunotherapy Goes Viral

Immunotherapy Goes Viral

VIRUSES BLASTING CANCER   Last week, Johnson & Johnson (New Brunswick, NJ ) announced that their biotech arm Janssen Labs (Rariton, NJ) is investing up to $1 billion dollars to acquire BeneVir, a small biotech based in Rockville, Maryland, which focuses on...
Eye Of The Cytokine Storm

Eye Of The Cytokine Storm

THE FLASH OF THE FIRST CAR-T Last week’s much anticipated FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphocytic leukemia hails as the first gene therapy on the US  market. Classified as a “cell-based gene therapy,” Novartis’...
Therapeutic Antibody Primer

Therapeutic Antibody Primer

Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this...
Eye Of The Cytokine Storm

Eye Of The Cytokine Storm

Understanding CAR-T Safety Chimeric antigen receptor therapy (CAR-T) is our top technology pick of 2016, blazing trails in drug development with its innovative approach of using engineered immune cells to fight cancer. Despite its success in clinical trials, safety...
Antibody-Coupled T-Cell Receptor

Antibody-Coupled T-Cell Receptor

The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and...